Uveal Diseases: Clinical Trials

603 completed, 180 unknown, 113 recruiting, 105 terminated. 317 Phase 2, 188 Phase 1, 168 Not applicable, 144 Phase 3, 80 Phase 4.

By phase and status

Phase	Trials	Status
Phase 2	317	Completed 168, Terminated 43, Unknown 29, Recruiting 27, Active not recruiting 22, Withdrawn 18, Not yet recruiting 7, Enrolling by invitation 2, Suspended 1
Phase 1	188	Completed 97, Terminated 26, Recruiting 21, Active not recruiting 14, Unknown 14, Withdrawn 7, Not yet recruiting 5, Enrolling by invitation 3, Suspended 1
Not applicable	168	Completed 83, Unknown 38, Recruiting 22, Terminated 10, Active not recruiting 6, Withdrawn 6, Not yet recruiting 2, Enrolling by invitation 1
Phase 3	144	Completed 79, Terminated 24, Unknown 15, Recruiting 14, Active not recruiting 7, Withdrawn 4, Not yet recruiting 1
Phase 4	80	Completed 42, Unknown 16, Not yet recruiting 8, Terminated 5, Withdrawn 4, Recruiting 3, Active not recruiting 2
Early Phase 1	6	Completed 2, Terminated 2, Unknown 1, Withdrawn 1

Follow Uveal Diseases: new trials by email Literature Review of Uveal Diseases trials Research Report on Uveal Diseases

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Locoregional Administration of TIL and Lymphodepletion in Patients With Melanoma and Liver Metastases Autologous Tumor Infiltrating Lymphocytes, Melphalan, Interleukin-2 - Uveal Melanoma, Metastatic Cutaneous Melanoma	Phase 1	Not yet recruiting	Vastra Gotaland Region	6	2027-01-31	2026-09-09
Locoregional or Systemic Administration of Autologous Tumor Infiltrating Lymphocytes in Patients With Metastatic Melanoma Autologous Tumor Infiltrating Lymphocytes (TIL), Melphalan, Interleukin-2 - Metastatic Uveal Melanoma, Metastatic Cutaneous Melanoma	Phase 1	Not yet recruiting	Vastra Gotaland Region	18	2027-01-01	2026-09-09
Prospective Trial of the Efficacy and Safety of a Personalized Regimen of High-dose Aflibercept 8mg on Treatment-naive Polypoidal Choroidal Vasculopathy: the PALLAS Trial aflibercept 8 mg - Polypoidal Choroidal Vasculopathy, Polypoidal Choroidal Vasculopathy (PCV)	Phase 3	Recruiting	Yeungnam University College of Medicine	50	2026-12-24	2026-02-05
Therapeutic Drug Monitoring-baSed adalimuMab De-escalatiOn in nOn-infecTious cHronic Uveitis Blood sample, Adalimumab Injection - Uveitis, Chronic Disease	Phase 4	Not yet recruiting	Centre Hospitalier Universitaire de Saint Etienne	320	2026-12-01	2026-07-10
Safety and Efficacy Study in Adults With Advanced Solid Tumors Receiving REGN13089-M404-M2980, an Antibody-drug Conjugate That Targets MET Protein on Tumors REGN13089-M404-M2980 - Advanced Solid Tumors	Phase 1 / Phase 2	Not yet recruiting	Regeneron Pharmaceuticals	320	2026-11-23	2026-10-07
Low Dose Dexamethasone for the Prevention of Cytokine Release Syndrome Associated With Tebentafusp Dexamethasone - Uveal Melanoma, Metastatic	Phase 2	Not yet recruiting	University of California, San Diego	34	2026-11-01	2026-09-03
Systemic and Topical Antiviral Control of Cytomegalovirus Anterior Uveitis: Treatment Outcomes - Trials I and II Valganciclovir, Ganciclovir (GCV), Placebo - Cytomegalovirus (CMV), Anterior Uveitis	Phase 2	Not yet recruiting	University of California, San Francisco	117	2026-11-01	2026-08-11
A Clinical Trial Of Tulisokibart In Participants With Active, Non-Infectious Uveitis (MK-7240-019) Tulisokibart, Placebo, Background prednisone therapy - Noninfectious Intermediate, Posterior, or Panuveitis	Phase 2	Not yet recruiting	Merck Sharp & Dohme LLC	87	2026-10-27	2026-10-06
Morpho-functional Evaluation of the Retina and Choroid Using Multimodal Imaging in Healthy Subjects and Patients With Retino-choroidal Diseases Retinal Diseases, Choroidal Diseases		Not yet recruiting	Fondazione G.B. Bietti, IRCCS	125	2026-10-01	2026-09-04
Study of Neoadjuvant RBP-01 In Patients With Primary Uveal Melanoma RBP-01 - Uveal Melanoma	Phase 1 / Phase 2	Not yet recruiting	ReBio Pharma	30	2026-10-01	2026-08-05
Clinical, Laboratory, and Therapeutic Analysis of Behçet's Disease in Assiut Behçet's Disease		Not yet recruiting	Assiut University	30	2026-09-30	2025-09-05
Serum EBI-3 Protein Levels in Behçet's Disease Behçet Disease		Not yet recruiting	Assiut University	90	2026-09-26	2026-09-28
Topical Insulin for Glaucoma (TING2) EYED-002 Low Dose (721 U/mL topical insulin), EYED-002 High Dose (1442 U/mL topical insulin), EYED-002 (highest tolerated dose, 12-month) - Open Angle Glaucoma, Primary Open Angle Glaucoma	Phase 1 / Phase 2	Enrolling by invitation	Stanford University	90	2026-09-10	2026-10-13
PANDA-ASOCT: Paediatric Anterior Uveitis Detection With Automated Image Analysis Using ASOCT Slit Lamp Examination, Anterior segment ocular coherence tomography (ASOCT) - Uveitis		Recruiting	Sheffield Children's NHS Foundation Trust	300	2026-09-09	2026-09-15
Speculum-Free Intravitreal Injection Using Cotton-Tipped Applicator Retraction: Pain, Procedure Time, Patient Satisfaction, and Safety Eyelid Speculum Retraction, Cotton-Tipped Applicator Retraction - Neovascular Age-Related Macular Degeneration (nAMD), Diabetic Macular Edema	Not applicable	Active not recruiting	Jakkrit Juhong	129	2026-09-09	2026-09-25
A Study to Evaluate the Efficacy and Safety of VIS-101 in Participants With Neovascular Age-Related Macular Degeneration VIS-101 6.0mg Low concentration, VIS-101 6.0mg High concentration, VIS-101 9.0mg High concentration - Neovascular Age Related Macular Degeneration(nAMD)	Phase 2	Not yet recruiting	Everest Medicines (China) Co.,Ltd.	244	2026-09-01	2026-09-10
Inflammatory Disease Biobank for Immunophenotyping and Cardiovascular Research Pericarditis, Tako-TSUBO Cardiomyopathy		Not yet recruiting	Assistance Publique - Hôpitaux de Paris	300	2026-09-01	2026-08-10
Corticotropin for Behçet's Disease: A Multicenter Randomized Controlled TrialAcronym. Repository Corticotropin Injection (ACTH), Study-matched inactive placebo injection, also called control injection - Behçet's Syndrome, Behçet's Syndrome (BS)	Phase 2	Not yet recruiting	Peking University People's Hospital	60	2026-09-01	2026-09-22
Asprosin in Behect Patients Behcet Disease		Not yet recruiting	Assiut University	44	2026-09-01	2026-09-03
Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma Darovasertib, Crizotinib (Xalkori) - Uveal Melanoma	Phase 3	Recruiting	IDEAYA Biosciences	450	2026-09-01	2026-09-15

Showing 20 of 1152. Sign in to see all of them.

Narrower conditions

Uveal Melanoma (279)  ·  Uveitis (268)  ·  Choroidal Neovascularization (203)  ·  Macular Degeneration (148)  ·  Behcet Syndrome (131)  ·  Melanoma (125)  ·  Exfoliation Syndrome (72)  ·  Uveitis, Posterior (60)  ·  Uveitis, Intermediate (56)  ·  Macular Edema (54)  ·  Polypoidal Choroidal Vasculopathy (50)  ·  Uveitis, Anterior (48)  ·  Glaucoma, Open-Angle (40)  ·  Panuveitis (37)  ·  Choroideremia (34)

Broader conditions

Eye Diseases (1133)  ·  Pathological Conditions, Signs and Symptoms (356)  ·  Pathologic Processes (337)  ·  Choroid Diseases (326)  ·  Neoplasms by Histologic Type (291)  ·  Neoplasms by Site (291)  ·  Skin and Connective Tissue Diseases (288)  ·  Neoplasms, Nerve Tissue (282)  ·  Neuroectodermal Tumors (282)  ·  Neoplasms, Germ Cell and Embryonal (281)  ·  Nevi and Melanomas (281)  ·  Neuroendocrine Tumors (279)  ·  Skin Diseases (278)  ·  Uveal Neoplasms (277)

Interventions

Ranibizumab (78)  ·  aflibercept (37)  ·  Ipilimumab (29)  ·  Adalimumab (26)  ·  Bevacizumab (26)  ·  Nivolumab (23)  ·  Verteporfin (20)  ·  Triamcinolone Acetonide (18)  ·  Blood Specimen Collection (15)  ·  Cyclophosphamide (15)  ·  Dexamethasone (15)  ·  Methotrexate (15)  ·  pembrolizumab (14)  ·  Interleukin-2 (11)  ·  salicylhydroxamic acid (11)

Sponsors

National Eye Institute (NEI) (58)  ·  Novartis Pharmaceuticals (36)  ·  Assiut University (31)  ·  National Cancer Institute (NCI) (22)  ·  Assistance Publique - Hôpitaux de Paris (17)  ·  Medical University of Vienna (15)  ·  Institut Curie (13)  ·  Memorial Sloan Kettering Cancer Center (11)  ·  Vastra Gotaland Region (11)  ·  Benha University (10)  ·  Novartis (10)  ·  Oregon Health and Science University (10)  ·  M.D. Anderson Cancer Center (9)  ·  Peking Union Medical College Hospital (9)  ·  Sun Yat-sen University (9)

Countries

United States (506)  ·  France (120)  ·  Germany (91)  ·  United Kingdom (90)  ·  Spain (69)  ·  China (68)  ·  Italy (67)  ·  Canada (61)  ·  Australia (55)  ·  Turkey (Türkiye) (52)  ·  Austria (43)  ·  Egypt (37)  ·  Israel (37)  ·  Switzerland (37)  ·  South Korea (36)

Top investigators

Hatice N Sen, M.D. (8)  ·  Quan D Nguyen, MD, MSc (6)  ·  Jeffrey S. Weber, MD, PhD (5)  ·  Nisha Acharya, MD MS (5)  ·  Fereydoun Davatchi, MD (4)  ·  Peter A. Merkel, MD, MPH (4)  ·  Thomas Ciulla, MD (4)

Results publications

PMID 30957581, PMID 37172782, PMID 23290985, PMID 30194931, PMID 30986442, PMID 36787524, PMID 19248087, PMID 19726427, PMID 20498207, PMID 21622969, PMID 21885496, PMID 22426346, PMID 23084240, PMID 24113783, PMID 25667295, PMID 28426849, PMID 29528792, PMID 32374423, PMID 33207259, PMID 34968756, PMID 36399237, PMID 36912792, PMID 37316690, PMID 37343623, PMID 38925285, PMID 39033924, PMID 11071039, PMID 11152054, PMID 11153967, PMID 11297486, PMID 11459787, PMID 11468137, PMID 11642370, PMID 11741106, PMID 12039921, PMID 12095806, PMID 12441176, PMID 12459649, PMID 12637048, PMID 12684398, PMID 12707595, PMID 12826605, PMID 12947072, PMID 12967792, PMID 14078870, PMID 14078872, PMID 14557174, PMID 15013874, PMID 15079763, PMID 15161982

NIH funding

2009 (13), 2019 (8), 2023 (6), 2014 (5), P30CA008748 (4), 2025 (3), N01CM00039 (3), 2008 (2), 2015 (2), 2016 (2), 2017 (2), N01CM00100 (2), N01CM62203 (2), N01CM62206 (2), P30CA006973 (2)